IPP Bureau
Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure
By IPP Bureau - February 05, 2026
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Zydus receives FDA’s tentative approval for Dapagliflozin Tablets
By IPP Bureau - February 05, 2026
Lupin launches Topiramate ER capsules in US
By IPP Bureau - February 05, 2026
Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR Extended-Release Capsules of Supernus Pharmaceuticals
Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility
By IPP Bureau - February 05, 2026
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Novo Nordisk weathers pricing pressure, bets big on oral Wegovy
By IPP Bureau - February 05, 2026
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth
By IPP Bureau - February 05, 2026
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook
By IPP Bureau - February 05, 2026
AstraZeneca & Daiichi Sankyo gain priority review for Datroway in hard-to-treat breast cancer
By IPP Bureau - February 05, 2026
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
FDA reviews AstraZeneca’s Saphnelo for subcutaneous use in Lupus
By IPP Bureau - February 05, 2026
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
GPT Healthcare reports 12% revenue growth in 9M FY26, strengthens clinical capabilities
By IPP Bureau - February 04, 2026
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
Sanofi’s Venglustat shows breakthrough results in rare neurological Gaucher disease
By IPP Bureau - February 04, 2026
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
FDA launches PreCheck program to bring drug manufacturing back to US
By IPP Bureau - February 04, 2026
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
Richter’s FYLREVY to transform menopause care in Europe?
By IPP Bureau - February 04, 2026
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
ALX Oncology’s evorpacept shows promise in HER2-positive breast cancer
By IPP Bureau - February 04, 2026
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
Siemens Healthineers launches €10 million R&D hub in Swords, Ireland
By IPP Bureau - February 04, 2026
The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders
